These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38946578)

  • 1. Genetically Engineered Membrane-Coated Nanoparticles for Enhanced Prostate-Specific Membrane Antigen Targeting and Ferroptosis Treatment of Castration-Resistant Prostate Cancer.
    Li Y; Li H; Zhang K; Xu C; Wang J; Li Z; Zhou Y; Liu S; Zhao X; Li Z; Yang F; Hu W; Jing Y; Wu P; Zhang J; Shi C; Zhang R; Jiang W; Xing N; Wen W; Han D; Qin W
    Adv Sci (Weinh); 2024 Sep; 11(33):e2401095. PubMed ID: 38946578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP1 inhibits RSL3-induced castration-resistant prostate cancer cell ferroptosis by driving glutamine uptake and metabolism to GSH.
    Fu X; Wu H; Li C; Deng G; Chen C
    Mol Cell Biochem; 2024 Sep; 479(9):2415-2427. PubMed ID: 37773303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.
    Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X
    Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death.
    Wu L; Liu F; Yin L; Wang F; Shi H; Zhao Q; Yang F; Chen D; Dong X; Gu Y; Xing N
    Cancer Commun (Lond); 2022 Aug; 42(8):768-783. PubMed ID: 35706368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
    Shi SJ; Wang LJ; Han DH; Wu JH; Jiao D; Zhang KL; Chen JW; Li Y; Yang F; Zhang JL; Zheng GX; Yang AG; Zhao AZ; Qin WJ; Wen WH
    Theranostics; 2019; 9(5):1247-1263. PubMed ID: 30867828
    [No Abstract]   [Full Text] [Related]  

  • 6. Loss of AR-regulated AFF3 contributes to prostate cancer progression and reduces ferroptosis sensitivity by downregulating ACSL4 based on single-cell sequencing analysis.
    Fan A; Li Y; Zhang Y; Meng W; Pan W; Chen M; Ma Z; Chen W
    Apoptosis; 2024 Oct; 29(9-10):1679-1695. PubMed ID: 38478171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
    Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
    Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis.
    Zou P; Chen Z; He Q; Zhuo Y
    Prostate; 2024 Jan; 84(1):64-73. PubMed ID: 37750290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.
    Zhang H; Zhou Y; Feng Y; Hou W; Chen Y; Xing Z; Zhang Y; Wei Q; Yin Y; Guo J; Hu H
    Clin Transl Med; 2024 May; 14(5):e1678. PubMed ID: 38736108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration‑resistant prostate cancer.
    Yang Y; Liu T; Hu C; Xia H; Liu W; Chen J; Wu S; Jiang Y; Xu Y; Liu W; Zhao L
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Hernandez-Hoyos G; Sewell T; Bader R; Bannink J; Chenault RA; Daugherty M; Dasovich M; Fang H; Gottschalk R; Kumer J; Miller RE; Ravikumar P; Wiens J; Algate PA; Bienvenue D; McMahan CJ; Natarajan SK; Gross JA; Blankenship JW
    Mol Cancer Ther; 2016 Sep; 15(9):2155-65. PubMed ID: 27406985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells.
    Qin Z; Ou S; Xu L; Sorensen K; Zhang Y; Hu DP; Yang Z; Hu WY; Chen F; Prins GS
    Chem Biol Drug Des; 2021 May; 97(5):1059-1078. PubMed ID: 33470049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
    Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
    Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATF6α promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis.
    Zhao R; Lv Y; Feng T; Zhang R; Ge L; Pan J; Han B; Song G; Wang L
    Prostate; 2022 Apr; 82(5):617-629. PubMed ID: 35089606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer.
    Ghoochani A; Hsu EC; Aslan M; Rice MA; Nguyen HM; Brooks JD; Corey E; Paulmurugan R; Stoyanova T
    Cancer Res; 2021 Mar; 81(6):1583-1594. PubMed ID: 33483372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
    Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
    Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.